| 17.33 -0.29 (-1.65%) | 08-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.25 | 1-year : | 24.82 |
| Resists | First : | 18.2 | Second : | 21.25 |
| Pivot price | 15.28 |
|||
| Supports | First : | 14.81 | Second : | 12.72 |
| MAs | MA(5) : | 16.27 |
MA(20) : | 15.75 |
| MA(100) : | 13.06 |
MA(250) : | 18.04 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 85.6 |
D(3) : | 69.8 |
| RSI | RSI(14): 60.4  |
|||
| 52-week | High : | 32.7 | Low : | 8.8 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BBNX ] has closed below upper band by 12.3%. Bollinger Bands are 48.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 17.53 - 17.62 | 17.62 - 17.68 |
| Low: | 16.55 - 16.67 | 16.67 - 16.74 |
| Close: | 17.16 - 17.34 | 17.34 - 17.45 |
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Tue, 11 Aug 2026
Beta Bionics, Inc. Stock 12‑Month Price Target Raised to $20.31, Implies 24% Upside - tradingview.com
Fri, 07 Aug 2026
Beta Bionics (NASDAQ:BBNX) Shares Up 13.7% - Should You Buy? - marketbeat.com
Fri, 07 Aug 2026
Beta Bionics, Inc. (BBNX) Stock Analysis: 42% Potential Upside Amidst Innovative Diabetes Solutions - DirectorsTalk Interviews
Thu, 06 Aug 2026
Lazard Asset Management LLC Buys New Holdings in Beta Bionics, Inc. $BBNX - marketbeat.com
Fri, 31 Jul 2026
Beta Bionics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BBNX) 2026-07-31 - Seeking Alpha
Wed, 29 Jul 2026
Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 45 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 118.3 (%) |
| Shares Short | 6,610 (K) |
| Shares Short P.Month | 4,670 (K) |
| EPS | -1.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.69 |
| Profit Margin | -61.4 % |
| Operating Margin | -80 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -26.2 % |
| Qtrly Rev. Growth | 37.7 % |
| Gross Profit (p.s.) | 1.54 |
| Sales Per Share | 2.64 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -10.84 |
| PEG Ratio | 0 |
| Price to Book value | 3.04 |
| Price to Sales | 6.55 |
| Price to Cash Flow | -13.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|